Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Concludes Vysis Acquisition

NEW YORK, Nov. 30—Abbott Laboratories concluded its acquisition of Vysis as scheduled at midnight on November 29.

The pharmaceutical company commenced a cash tender offer on Oct. 31 to purchase all outstanding shares of the genomics-based disease management company. 

As a final step, remaining Vysis shareholders will receive the same $30.50 per share cash price as paid in the tender offer.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.